Staburo implements Git for Version Control in Statistical Programming 

Staburo implements Git for Version Control in Statistical Programming 

Staburo implements Git for Version Control in Statistical Programming 

At Staburo, we’re continuously improving the quality and efficiency of our statistical programming workflows. As part of this commitment, we have successfully integrated Git as a version control system into our established folder structure. 

This step enhances key aspects of our programming processes: 

  • Collaboration: Multiple team members can now work on the same project with full transparency and coordination. 
  • Traceability: Changes to code are clearly documented, making it easier to review and audit. 
  • Error Recovery: We can now revert to previous code states with precision, minimizing risks and downtime. 

Git is now embedded in both our SAS and R toolchains, which we use for delivering high-quality clinical research outputs. This integration aligns with our high standards for compliance and quality assurance, ensuring that every analysis is efficient, reproducible, and reliable. 

📬 Interested in working with us? 
Reach out to us, and we can explore your potential project together at : proposal@staburo.de.

Data analysis, clinical biostatistics and more.

Staburo at the ACDM Annual Conference 2025 in Prague

Staburo at the ACDM Annual Conference 2025 in Prague

Staburo at the ACDM Annual Conference 2025 in Prague

 

From March 2nd to 4th, Staburo colleagues Birte Clasen and Matthias Lehr attended the ACDM Annual Conference in Prague. With around 450 participants from over 180 organizations, the event brought together industry professionals for three days of knowledge-sharing, networking, and innovation.

Highlights included:

  • Inspiring plenary sessions, such as the inspiring talk by Alicia Staley (Medidata) on patient-centric clinical research, based on her personal journey as a cancer patient and clinical trial participant.
  • Breakout sessions covering key topics like Risk-based Quality Management (RBQM), Data Management Evolution, and Technology & Innovation.
  • Engaging discussions around Audit Trail Review as part of RBQM, and AI solutions for Clinical Data Management.
  • Poster presentations showcasing new research and approaches.
  • A dynamic Demo & Live Lounge featuring cutting-edge tools for EDC, ePRO, and eCOA systems.
  • Valuable networking opportunities at the evening socials, including a Conference Dinner with live music and awards.

Thank you to Birte Clasen and Matthias Lehr for representing Staburo’s Data Management Team and bringing back fresh insights!

 Learn more about our data management services.

Data analysis, clinical biostatistics and more.

Staburo supports transdisciplinary thesis advisory committee at TUM

Staburo supports transdisciplinary thesis advisory committee at TUM

Staburo supports transdisciplinary thesis advisory committee at TUM 

We’re happy to share that Staburo is supporting a Transdisciplinary Thesis Advisory Committee (TTAC) for a doctoral researcher at the Konrad Zuse School of Excellence in Reliable AI, based at TUM.

The TTAC is tailored to each doctoral researcher, combining perspectives from both academia and industry. We are contributing to the advisory committee of a PhD student working on a thesis that focuses on modelling causal systems with dynamic processes.

During regular meetings, we engage in discussions on the student’s progress, their individual development plan, and how to bridge their research with practical applications. As a representative from the industry, we’re proud to share industry insights and contribute to their academic journey.

At Staburo, we value the opportunity to support young researchers by offering mentorship and highlighting potential career pathways.

Data analysis, clinical biostatistics and more.

Staburo Strategic Initiative: Estimands and Endpoints

Staburo Strategic Initiative: Estimands and Endpoints

Staburo strategic initiative: Estimands and endpoints

Under the umbrella of our Staburo strategy 2027, we identified important topics for our industry and our company. Accordingly, a number of internal strategic initiatives, in which team members jointly work on these topics, were launched.

At the end of 2023, five Staburo statisticians and five disclosure managers and medical writers joined our initiative ‘Hot topics: Estimands and Endpoints’ led by Managing Director Hannes Buchner and spent over a year producing valuable results.

Our achievements include a poster at the 57th EMWA Conference in Valencia (‘An attempt to translate estimands into plain language’, Staburo @ 57th EMWA Conference in Valencia | Data science, biostatistics, data transparency, bioinformatics and statistical programming) and a poster at the PSI 2024 Conference in Amsterdam (‘Conditional vs Marginal Effects: A Systematic Review of OS and PFS on ClinicalTrials.gov’, Staburo @ PSI Conference 2024 | Data science, biostatistics, data transparency, bioinformatics and statistical programming ) as well as preparations for future conference contributions and a webinar about estimands and medical writing.

Moreover, we established participation as active members in the EMWA Regulatory Writing Group and in the Estimand Implementation Working Group (EIWG) from EFPIA in the subgroup ‘Reporting of Estimands’.

Other hands-on results are internal guideline documents and trainings for accurate and consistent definition of endpoints in clinical trial protocols, statistical analysis plans and for results disclosure, and four trainings about estimands and their implementation in clinical trial protocols tailored for our clients as well as two internal trainings.

We are proud to have strengthened Staburo’s expertise on this important topic building on previous work (including https://doi.org/10.1002/pst.2158, Staburo @ Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology? | Data science, biostatistics, data transparency, bioinformatics and statistical programming)  and are looking forward to the next strategic initiatives that have already started.

Contributing colleagues were Stephan Bischofberger, Gabriele Bleckert, Hannes Buchner, Marie-Paule Ehrhart, Habib Esmaeili, Ulrike Fischer, Anita Kociaj, Kathi Künnemann, Edith Küpper, Maarten van Dijk and Markus Waser.

Data analysis, clinical biostatistics and more.

Reflecting on PHUSE 2024

Reflecting on PHUSE 2024

Reflecting on PHUSE 2024

Wrapping up an exciting 2024 conference season and gearing up for an eventful 2025 for Staburo GmbH! 

Last November, we had the privilege of attending the Phuse EU Connect 2024 in beautiful Strasbourg, a flagship event for statistical programmers in drug development and healthcare. With over 700 attendees from 36 countries, it was the largest in-person connect yet – buzzing with insightful sessions, engaging discussions, and wonderful networking opportunities. 

Our colleagues Jannis Ströbele and Angelika Böhm represented Staburo, diving into a rich program of plenary and parallel sessions, workshops, and a lively poster session. They also made the most of the social events, from speed networking on Sunday to the grand gala dinner on Monday – truly an event to remember! 

As we look back on the many conferences we attended in 2024, we’re thrilled to share that our 2025 agenda is already packed! We can’t wait to reconnect and share insights at events like DAGStat, PSI conference, BIO International Convention, APF, BVMA symposium and many more! 

We’re looking forward to connecting with many of you at upcoming events! 

Data analysis, clinical biostatistics and more.